VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice

被引:93
作者
Enterlein, S
Warfield, KL
Swenson, DL
Stein, DA
Smith, JL
Gamble, CS
Kroeker, AD
Iversen, PL
Bavari, S
Mühlberger, E
机构
[1] Univ Marburg, Dept Virol, D-35043 Marburg, Germany
[2] USA, Med Res Inst Infect Dis, Frederick, MD 21702 USA
[3] AVI BioPharma Inc, Corvallis, OR USA
关键词
D O I
10.1128/AAC.50.3.984-993.2006
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Phosphorodiamidate morpholino oligomers (PMO) are a class of uncharged single-stranded DNA analogs modified such that each subunit includes a phosphorodiamidate linkage and morpholine ring. PMO antisense agents have been reported to effectively interfere with the replication of several positive-strand RNA viruses in cell culture. The filoviruses, Marburg virus and Ebola virus (EBOV), are negative-strand RNA viruses that cause up to 90% lethality in human outbreaks. There is currently no commercially available vaccine or efficacious therapeutic for any filovirus. In this study, PMO conjugated to arginine-rich cell-penetrating peptide (P-PMO) and nonconjugated PMO were assayed for the ability to inhibit EBOV infection in cell culture and in a mouse model of lethal EBOV infection. A 22-mer P-PMO designed to base pair with the translation start site region of EBOV VP35 positive-sense RNA generated sequence-specific and time- and dose-dependent inhibition of EBOV amplification in cell culture. The same oligomer provided complete protection to mice when administered before or after an otherwise lethal infection of EBOV. A corresponding nonconjugated PMO, as well as nonconjugated truncated versions of 16 and 19 base residues, provided length-dependent protection to mice when administered prophylactically. Together, these data suggest that antisense PMO and P-PMO have the potential to control EBOV infection and are promising therapeutic candidates.
引用
收藏
页码:984 / 993
页数:10
相关论文
共 43 条
  • [1] The Ebola virus VP35 protein functions as a type IIFN antagonist
    Basler, CF
    Wang, XY
    Mühlberger, E
    Volchkov, V
    Paragas, J
    Klenk, HD
    Garcia-Sastre, A
    Palese, P
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (22) : 12289 - 12294
  • [2] The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3
    Basler, CF
    Mikulasova, A
    Martinez-Sobrido, L
    Paragas, J
    Mühlberger, E
    Bray, M
    Klenk, HD
    Palese, P
    García-Sastre, A
    [J]. JOURNAL OF VIROLOGY, 2003, 77 (14) : 7945 - 7956
  • [3] Interactions of Marburg virus nucleocapsid proteins
    Becker, S
    Rinne, C
    Hofsäss, U
    Klenk, HD
    Mühlberger, E
    [J]. VIROLOGY, 1998, 249 (02) : 406 - 417
  • [4] A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever
    Bray, M
    Davis, K
    Geisbert, T
    Schmaljohn, C
    Huggins, J
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (03) : 651 - 661
  • [5] The evolving field of biodefence: Therapeutic developments and diagnostics
    Burnett, JC
    Henchal, EA
    Schmaljohn, AL
    Bavari, S
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (04) : 281 - 297
  • [6] Inhibition of flavivirus infections by antisense oligorners specifically suppressing viral translation and RNA replication
    Deas, TS
    Binduga-Gajewska, I
    Tilgner, M
    Ren, P
    Stein, DA
    Moulton, HM
    Iversen, PL
    Kauffman, EB
    Kramer, LD
    Shi, PY
    [J]. JOURNAL OF VIROLOGY, 2005, 79 (08) : 4599 - 4609
  • [7] Feldmann H, 1999, CURR TOP MICROBIOL, V235, P1
  • [8] Fisher-Hoch SP, 1999, CURR TOP MICROBIOL, V235, P117
  • [9] Inhibition of Marburg virus protein expression and viral release by RNA interference
    Fowler, T
    Bamberg, S
    Möller, P
    Klenk, HD
    Meyer, TF
    Becker, S
    Rudel, T
    [J]. JOURNAL OF GENERAL VIROLOGY, 2005, 86 : 1181 - 1188
  • [10] Geisbert Thomas W., 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404008300